GlassScriptPhysician profile
Christopher Duong Bui
NPI 1811061468
$145,415.21
in general payments reported to CMS, 2019-2025
44 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $13K · 2021: $21K · 2022: $16K · 2023: $16K · 2024: $19K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $12K · Travel and Lodging: $444 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,930.00 |
| Food and Beverage | $12,438.53 |
| Travel and Lodging | $443.71 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58,755.48 | 2019-2025 | Vemlidy, Epclusa, Livdelzi |
| Abbvie INC. | $58,550.01 | 2019-2025 | Creon, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13,348.79 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Nestle Healthcare Nutrition INC. | $1,958.78 | 2020-2023 | |
| Lilly USA, LLC | $1,641.78 | 2019-2025 | Taltz, Omvoh, Olumiant |
| Aimmune Therapeutics, INC. | $1,436.23 | 2024-2025 | Zenpep |
| Csl Behring | $943.36 | 2019-2023 | Hizentra |
| Amgen INC. | $888.78 | 2019-2025 | Repatha, Evenity |
| Ardelyx, INC. | $861.38 | 2022-2025 | Ibsrela |
| Allergan, INC. | $571.78 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $518.83 | 2019-2023 | Ocaliva |
| Madrigal Pharmaceuticals | $441.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $403.23 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $401.35 | 2023-2025 | Stelara, Tremfya |
| Stryker Corporation | $379.09 | 2022-2025 | Pangea |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $378.63 | 2019-2020 | |
| Redhill Biopharma INC. | $301.89 | 2022-2025 | Talicia, Aemcolo, Movantik |
| Ferring Pharmaceuticals INC. | $283.86 | 2023 | Rebyota |
| Janssen Scientific Affairs, LLC | $253.30 | 2022 | |
| Novo Nordisk INC | $249.66 | 2023-2025 | Wegovy, Novoseven |
| Leo Pharma INC. | $246.62 | 2023-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $238.61 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $232.33 | 2022-2024 | Linzess |
| Vivus LLC | $229.18 | 2021-2025 | Qsymia, Pancreaze |
| Takeda Pharmaceuticals U.S.A., INC. | $203.22 | 2019-2021 | |
| Covidien LP | $198.32 | 2019 | |
| Qol Medical, LLC | $183.56 | 2023-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $142.84 | 2025 | Barrx |
| Exact Sciences Corporation | $137.85 | 2023 | Cologuard Collection Kit |
| Celgene Corporation | $133.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $120.81 | 2019 | |
| Genzyme Corporation | $120.39 | 2022 | |
| Endogastric Solutions, INC | $116.31 | 2019 | |
| Apollo Endosurgery US INC | $111.07 | 2023 | Overstitch Endoscopic Suturing System |
| Braintree Laboratories, INC. | $101.39 | 2022-2024 | Suflave, Sutab |
| Amarin Pharma, INC. | $100.00 | 2019 | |
| Celltrion USA INC. | $94.88 | 2025 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $36.68 | 2025 | Iqirvo |
| Pfizer INC. | $24.24 | 2025 | |
| Dova Pharmaceuticals | $18.46 | 2019 | |
| Merck Sharp & Dohme LLC | $17.57 | 2019 | |
| Shire North American Group INC | $16.80 | 2019 | |
| Echosens North America, INC. | $11.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.